Repligen Corp. (RGEN) Rose as Industrial Destocking Decreased and Order Patterns Stabilized

Core Insights - Conestoga Capital Advisors reported that US equities had solid returns in 2025, with double-digit gains across major indices, but underlying conditions showed extreme volatility and market leadership [1] - The Small Cap Strategy of Conestoga Capital Advisors returned -1.89% net-of-fees in Q4 2025, underperforming the Russell 2000 Growth Index which returned 1.22% [1] - The rally in "low quality" stocks continued in Q4 2025, albeit at a slower pace compared to previous quarters [1] Company Insights: Repligen Corporation (NASDAQ:RGEN) - Repligen Corporation, a life science company, experienced a one-month return of -17.76% and a 52-week loss of 15.10%, with its stock closing at $138.11 and a market capitalization of $7.774 billion on February 18, 2026 [2] - The company supplies bioprocessing equipment and consumables for biologic drug manufacturing, and its shares rebounded as evidence suggested that industry destocking had bottomed and order trends were stabilizing [3] - Improved visibility into growth for 2026 and disciplined cost controls have led to higher expectations for operating leverage, prompting a market re-rating of the stock [3] Hedge Fund Interest - Repligen Corporation was held by 53 hedge fund portfolios at the end of Q3 2025, an increase from 49 in the previous quarter, indicating growing interest among institutional investors [4] - Despite acknowledging Repligen's potential, the company believes that certain AI stocks present greater upside potential and lower downside risk [4]